Sangeeta Hingorani1,2,3, Emily Pao3, Phil Stevenson2, Gary Schoch2, Benjamin L Laskin4, Ted Gooley2, George B McDonald5,2. 1. Division of Pediatrics and Medicine, University of Washington, Clinical Research Division, sangeeta.hingorani@seattlechildrens.org. 2. Fred Hutchinson Cancer Research Center and. 3. Division of Nephrology, Seattle Children's Hospital, Seattle, Washington; and. 4. Division of Nephrology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 5. Division of Pediatrics and Medicine, University of Washington, Clinical Research Division.
Abstract
BACKGROUND AND OBJECTIVES: Kidney injury is a significant complication for patients undergoing hematopoietic cell transplantation (HCT), but few studies have prospectively examined changes in GFR in long-term survivors of HCT. We described the association between changes in GFR and all-cause mortality in patients up to 10 years after HCT. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective, observational cohort study of adult patients undergoing HCT at the Fred Hutchinson Cancer Center in Seattle, Washington from 2003 to 2015. Patients were followed from baseline, before conditioning therapy, until a maximum of 10 years after transplant. We used Cox proportional hazard models to examine the association between creatinine eGFR and all-cause mortality. We used time-dependent generalized estimating equations to examine risk factors for decreases in eGFR. RESULTS: A total of 434 patients (median age, 52 years; range, 18-76 years; 64% were men; 87% were white) were followed for a median 5.3 years after HCT. The largest decreases in eGFR occurred within the first year post-transplant, with the eGFR decreasing from a median of 98 ml/min per 1.73 m2 at baseline to 78 ml/min per 1.73 m2 by 1 year post-HCT. Two thirds of patients had an eGFR<90 ml/min per 1.73 m2 at 1 year after transplant. When modeled as a continuous variable, as eGFR declined from approximately 60 ml/min per 1.73 m2, the hazard of mortality progressively increased relative to a normal eGFR of 90 ml/min per 1.73 m2 (P<0.001). For example, when compared with an eGFR of 90 ml/min per 1.73 m2, the hazard ratios for eGFR of 60, 50, and 40 ml/min per 1.73 m2 are 1.15 (95% confidence interval, 0.87 to 1.53), 1.68 (95% confidence interval, 1.26 to 2.24), and 2.67 (95% confidence interval, 1.99 to 3.60), respectively. Diabetes, hypertension, acute graft versus host disease, and cytomegalovirus infection were independently associated with a decline in GFR, whereas calcineurin inhibitor levels, chronic graft versus host disease, and albuminuria were not. CONCLUSIONS: Adult HCT recipients have a high risk of decreased eGFR by 1 year after HCT. Although eGFR remains fairly stable thereafter, a decreased eGFR is significantly associated with higher risk of mortality, with a progressively increased risk as eGFR declines.
BACKGROUND AND OBJECTIVES:Kidney injury is a significant complication for patients undergoing hematopoietic cell transplantation (HCT), but few studies have prospectively examined changes in GFR in long-term survivors of HCT. We described the association between changes in GFR and all-cause mortality in patients up to 10 years after HCT. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective, observational cohort study of adult patients undergoing HCT at the Fred Hutchinson Cancer Center in Seattle, Washington from 2003 to 2015. Patients were followed from baseline, before conditioning therapy, until a maximum of 10 years after transplant. We used Cox proportional hazard models to examine the association between creatinineeGFR and all-cause mortality. We used time-dependent generalized estimating equations to examine risk factors for decreases in eGFR. RESULTS: A total of 434 patients (median age, 52 years; range, 18-76 years; 64% were men; 87% were white) were followed for a median 5.3 years after HCT. The largest decreases in eGFR occurred within the first year post-transplant, with the eGFR decreasing from a median of 98 ml/min per 1.73 m2 at baseline to 78 ml/min per 1.73 m2 by 1 year post-HCT. Two thirds of patients had an eGFR<90 ml/min per 1.73 m2 at 1 year after transplant. When modeled as a continuous variable, as eGFR declined from approximately 60 ml/min per 1.73 m2, the hazard of mortality progressively increased relative to a normal eGFR of 90 ml/min per 1.73 m2 (P<0.001). For example, when compared with an eGFR of 90 ml/min per 1.73 m2, the hazard ratios for eGFR of 60, 50, and 40 ml/min per 1.73 m2 are 1.15 (95% confidence interval, 0.87 to 1.53), 1.68 (95% confidence interval, 1.26 to 2.24), and 2.67 (95% confidence interval, 1.99 to 3.60), respectively. Diabetes, hypertension, acute graft versus host disease, and cytomegalovirus infection were independently associated with a decline in GFR, whereas calcineurin inhibitor levels, chronic graft versus host disease, and albuminuria were not. CONCLUSIONS: Adult HCT recipients have a high risk of decreased eGFR by 1 year after HCT. Although eGFR remains fairly stable thereafter, a decreased eGFR is significantly associated with higher risk of mortality, with a progressively increased risk as eGFR declines.
Authors: Sangeeta R Hingorani; Katherine Guthrie; Ami Batchelder; Gary Schoch; Nada Aboulhosn; Janel Manchion; George B McDonald Journal: Kidney Int Date: 2005-01 Impact factor: 10.612
Authors: Sangeeta Hingorani; Laura S Finn; Emily Pao; Rick Lawler; Gary Schoch; George B McDonald; Behzad Najafian; Brenda Sandmaier; Ted Gooley Journal: Clin J Am Soc Nephrol Date: 2014-11-11 Impact factor: 8.237
Authors: T Shimoi; M Ando; W Munakata; T Kobayashi; K Kakihana; K Ohashi; H Akiyama; H Sakamaki Journal: Bone Marrow Transplant Date: 2012-05-28 Impact factor: 5.483
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: I Sakellari; A Barbouti; G Bamichas; D Mallouri; P Kaloyannidis; S Fragidis; I Batsis; C Apostolou; A Karpouza; E Yannaki; C Smias; K Sombolos; A Anagnostopoulos Journal: Bone Marrow Transplant Date: 2013-04-15 Impact factor: 5.483
Authors: Siribha Changsirikulchai; David Myerson; Katherine A Guthrie; George B McDonald; Charles E Alpers; Sangeeta R Hingorani Journal: Clin J Am Soc Nephrol Date: 2009-01-14 Impact factor: 8.237
Authors: Sonata Jodele; Christopher E Dandoy; Adam Lane; Benjamin L Laskin; Ashley Teusink-Cross; Kasiani C Myers; Gregory Wallace; Adam Nelson; Jack Bleesing; Ranjit S Chima; Russel Hirsch; Thomas D Ryan; Stefanie Benoit; Kana Mizuno; Mikako Warren; Stella M Davies Journal: Blood Date: 2020-03-26 Impact factor: 22.113
Authors: Amanda DeMauro Renaghan; Edgar A Jaimes; Jolanta Malyszko; Mark A Perazella; Ben Sprangers; Mitchell Howard Rosner Journal: Clin J Am Soc Nephrol Date: 2019-12-13 Impact factor: 8.237
Authors: Nosha Farhadfar; Ajoy Dias; Tao Wang; Caitrin Fretham; Saurabh Chhabra; Hemant S Murthy; Larisa Broglie; Anita D'Souza; Shahinaz M Gadalla; Robert Peter Gale; Shahrukh Hashmi; A Samer Al-Homsi; Gerhard C Hildebrandt; Peiman Hematti; David Rizzieri; Lynette Chee; Hillard M Lazarus; Christopher Bredeson; Edgar A Jaimes; Amer Beitinjaneh; Asad Bashey; Tim Prestidge; Maxwell M Krem; David I Marks; Stefanie Benoit; Jean A Yared; Taiga Nishihori; Richard F Olsson; Cesar O Freytes; Edward Stadtmauer; Bipin N Savani; Mohamed L Sorror; Siddhartha Ganguly; John R Wingard; Marcelo Pasquini Journal: Transplant Cell Ther Date: 2021-02-26
Authors: Hao Dai; Olaf Penack; Aleksandar Radujkovic; David Schult; Joshua Majer-Lauterbach; Igor Wolfgang Blau; Lars Bullinger; Sihe Jiang; Carsten Müller-Tidow; Peter Dreger; Thomas Luft Journal: Bone Marrow Transplant Date: 2021-01-30 Impact factor: 5.483
Authors: Karyne Pelletier; Gabrielle Côté; Kayla Madsen; Shiyi Chen; S Joseph Kim; Christopher T Chan; Jonas Mattsson; Ivan Pasic; Abhijat Kitchlu Journal: Clin Kidney J Date: 2022-04-07